New PET tracer could light up cancers for better detection
NCT ID NCT04459273
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 40 times
Summary
This early-phase study is testing a new imaging tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. Researchers will give the tracer to 26 patients with various cancers and use PET/CT scans to see where it goes in the body. They will also compare the scan results with tissue samples to validate the findings. The goal is to see if this tracer can help improve cancer imaging in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT BRAIN NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gallium Ga 68 FAPi-46 (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this could lead to a new imaging method to better detect and understand various cancers, potentially improving diagnosis and treatment planning.
What could go wrong
This is a very early (Phase 1) exploratory study with only 26 participants, so results may not apply to all patients. The tracer's effectiveness for diagnosis is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.